Scholarlink

Objectives <p>We report the case of an adult-type diffuse glioma with spinal leptomeningeal dissemination, corresponding to a new molecularly methylation class, identified as "Adult-type diffuse high-grade glioma, <i>IDH</i>-wildtype, subtype E," using the Heidelberg Epignostix CNS Tumor Classifier v12.8.</p> Methods <p>Clinical, histo-molecular, cerebrospinal fluid analyses and neuro-radiological data were recorded.</p> Results <p>A 43-year-old man was diagnosed 5&#xa0;years ago with a diffuse glioma and subsequent spinal leptomeningeal dissemination. He received radiochemotherapy based on temozolomide followed by monthly temozolomide (6&#xa0;months) but relapsed 15&#xa0;months later. After three additional therapeutic lines, bevacizumab was introduced, achieving a clinical and imaging response with subtotal regression of lesions. To date, glioblastoma remains under control, 5&#xa0;years after diagnosis and 3&#xa0;years after bevacizumab introduction.</p> Discussion <p>We describe an unusual prolonged response to bevacizumab in a new subtype of adult-type diffuse high-grade glioma, with spinal leptomeningeal dissemination. Despite frequent dreadful prognosis in patients treated for high-grade gliomas, there are rare long-term responder patients. This situation remains unclear, particularly in the context of spinal leptomeningeal dissemination. The identification of new subtypes could help differentiate between miscellaneous prognostic group. It would be relevant to consider these subgroups in future clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Adèle Meola,
  • Romain Appay,
  • Benoit Testud,
  • Gregorio Petrirena,
  • Chantal Campello,
  • Maryline Barrié,
  • Alexandre Bertucci,
  • Didier Autran,
  • Thomas Graillon,
  • Kaissar Farah,
  • Laetitia Padovani,
  • Isabelle Pougnet,
  • Isabelle Nanni,
  • Olivier Chinot,
  • Emeline Tabouret,
  • Vincent Harlay

摘要

Objectives

We report the case of an adult-type diffuse glioma with spinal leptomeningeal dissemination, corresponding to a new molecularly methylation class, identified as "Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E," using the Heidelberg Epignostix CNS Tumor Classifier v12.8.

Methods

Clinical, histo-molecular, cerebrospinal fluid analyses and neuro-radiological data were recorded.

Results

A 43-year-old man was diagnosed 5 years ago with a diffuse glioma and subsequent spinal leptomeningeal dissemination. He received radiochemotherapy based on temozolomide followed by monthly temozolomide (6 months) but relapsed 15 months later. After three additional therapeutic lines, bevacizumab was introduced, achieving a clinical and imaging response with subtotal regression of lesions. To date, glioblastoma remains under control, 5 years after diagnosis and 3 years after bevacizumab introduction.

Discussion

We describe an unusual prolonged response to bevacizumab in a new subtype of adult-type diffuse high-grade glioma, with spinal leptomeningeal dissemination. Despite frequent dreadful prognosis in patients treated for high-grade gliomas, there are rare long-term responder patients. This situation remains unclear, particularly in the context of spinal leptomeningeal dissemination. The identification of new subtypes could help differentiate between miscellaneous prognostic group. It would be relevant to consider these subgroups in future clinical trials.